FDA authorizes emergency use of Regeneron antibody treatment given to Trump - Axios
Please enter a valid email.Please enter a valid email.Please enter a valid email.Please enter a valid email.Please enter a valid email.Please enter a valid email.Please enter a valid email.Please enter a valid email.Why it matters: Regeneron's two monoclonal antibodies, casirivimab and imdevimab, are for people who tested positive for the coronavirus and "who are at high risk for progressing to severe COVID-19," including people who are 65 and older, and/or people with certain chronic illnesses, per an FDA statement.